Codex Labs Shaant Skin De-Stress Supplement 2.0 for Female Hormonal Acne Is Launched with Clinical Study Results
'At Codex Labs, we are focused on studying the interactions between skin-gut-brain-microbiome axes and hormonal imbalance or gut dysbiosis, to develop next-generation solutions for skin conditions such as acne,' says Dr. Barbara Paldus, CEO, Codex Labs. 'These new systems will require integration of topicals with core supplements, diet, lifestyle, and mental health, to achieve optimum clearance.'
The Shaant Skin De-Stress Supplement was formulated in partnership with Dr. Jessica Maloh, N.D., an integrative naturopathic doctor, and Dr. Raja Sivamani, an integrative board-certified dermatologist and Ayurvedic practitioner.
'Research suggests that myo-inositol, a dietary supplement, may be helpful for PCOS-related acne,' says Dr. Maloh. 'The mechanism of action may be related to its ability to lower androgen levels and support healthy glucose metabolism. However, to address other contributors and aggravators to acne, we wanted to formulate a supplement that also addresses gut health, psychological stress, and inflammation.'
The Shaant Skin De-Stress Supplement 2.0 is formulated with herbal and active ingredients designed to support hormonal balance (myo-inositol), metabolic health (milk thistle, barberry, myo-inositol), and psychological stress relief (l-theanine and holy basil), while improving gut microbiome diversity and managing the acne inflammasome (MSM and turmeric).
In an independent clinical trial at Integrative Skin Science and Research involving 36 male and female subjects with mild to moderate acne, the measured improvement after 8 weeks of Shaant Skin De-Stress Herbal Supplement use included:
Significant reductions in estrone, 17-OHP, and androstenedione suggested notable effects on steroid hormone metabolism. Progesterone also showed a consistent downward trend across both time points in the study. Complete results are published in Dermatology and Therapy (https://link.springer.com/article/10.1007/s13555-025-01411-4).
All products are manufactured in a high-tech, cGMP-compliant facility, and each batch is third-party tested to ensure the highest quality.
About Codex Labs
Based in Silicon Valley and led by scientist Dr. Barb Paldus, Codex Labs is committed to creating highly effective, clinically proven, microbiome-supporting skin-gut-brain-biome solutions that contain potent, biotech-derived plant-based actives. Our products are focused on restoring/protecting the skin barrier, managing inflammation, and addressing skin conditions associated with aging, acne, eczema, and psoriasis. The brand has been heralded by integrative dermatologists and naturopathic doctors for creating the next generation of effective, vegan, cruelty-free, and sustainable dermaceutical solutions.
Media Contact
Company Name: Otter Public Relations
Contact Person: Anna Kate Womack
Email: Send Email
Phone: 7032323140
City: ORLANDO
State: FL
Country: United States
Website: www.otterpr.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
28 minutes ago
- CTV News
An Ohio couple welcomes a baby boy from a nearly 31-year-old frozen embryo
About two per cent of U.S. births are the result of in vitro fertilization, even less come from donated embryos. A baby boy born last week to an Ohio couple developed from an embryo that had been frozen for more than 30 years in what is believed to be a record length of storage time before a birth. In what's known as embryo adoption, Linda and Tim Pierce used a handful of embryos donated in 1994 in their pursuit of having a child after fighting infertility for years. Their son was born Saturday from an embryo that had been in storage for 11,148 days, which the Pierces' doctor says sets a record. It's a concept that has been around since the 1990s but is gaining attraction as some fertility clinics and advocates, often Christian-centered, oppose discarding leftover embryos because of their belief that life begins at or around conception and that all embryos deserve to be treated like children who need a home. 'I felt all along that these three little hopes, these little embryos, deserved to live just like my daughter did,' said Linda Archerd, 62, who donated her embryos to the Pierces. Just about two per cent of births in the U.S. are the result of in vitro fertilization, and an even smaller fraction involve donated embryos. However, medical experts estimate about 1.5 million frozen embryos are currently being stored throughout the country, with many of those in limbo as parents wrestle with what to do with their leftover embryos created in IVF labs. Further complicating the topic is a 2024 Alabama Supreme Court decision that said that frozen embryos have the legal status of children. State leaders have since devised a temporary solution shielding clinics from liability stemming from that ruling, though questions linger about remaining embryos. Archerd says she turned to IVF in 1994. Back then, the ability to freeze, thaw and transfer embryos was making key progress and opening the door for hopeful parents to create more embryos and increase their chances of a successful transfer. She wound up with four embryos and initially hoped to use them all. But after the birth of her daughter, Archerd and her husband divorced, disrupting her timeline for having more children. As the years turned into decades, Archerd said she was wracked with guilt about what to do with the embryos as storage fees continued to rise. Eventually, she found Snowflakes, a division of Nightlight Christian Adoptions, which offers open adoptions to donors. Archerd was also able to set preferences for what families would adopt her embryos. 'I wanted to be a part of this baby's life,' she said. 'And I wanted to know the adopting parents.' The process was tricky, requiring Archerd to contact her initial fertility doctor in Oregon and dig through paper records to get the proper documentation for the donation. The embryos then had to be shipped from Oregon to the Pierces' doctor in Tennessee. The clinic, Rejoice Fertility in Knoxville, refuses to discard frozen embryos and has become known for handling embryos stored in outdated and older containers. Of the three donated embryos the Pierces received from Archerd, one didn't make the thaw. Two were transferred to Lindsey Pierce's womb, but just one successfully implanted. According to Dr. John David Gordon, the transfer of the nearly 31-year-old embryo marks the longest-frozen embryo to result in a live birth. He would know, Gordon says his clinic assisted in the previous record, when Lydia and Timothy Ridgeway were born from embryos frozen for 30 years, or 10,905 days. 'I think that these stories catch the imagination,' Gordon said. 'But I think they also provide a little bit of a cautionary tale to say: Why are these embryos sitting in storage? You know, why do we have this problem?' In a statement, Lindsey and Tim Pierce said the clinic's support was just what they needed. 'We didn't go into this thinking about records — we just wanted to have a baby,' Lindsey Pierce said. For Archerd, the donation process has been an emotional roller coaster. Relief that her embryos finally found a home, sadness it couldn't be with her and a little anxiety about what the future holds next, with possibly meeting the Pierces and the baby in person. 'I'm hoping that they're going to send pictures,' she said, noting that the parents have already sent several after the birth. 'I'd love to meet them some day. That would be a dream come true to meet — meet them and the baby.' Kimberlee Kruesi, The Associated Press
Globe and Mail
2 hours ago
- Globe and Mail
Frequency Electronics Announces 2025 Quantum Sensing Summit in New York City
MITCHEL FIELD, N.Y., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Frequency Electronics, Inc. ('FEI' or the 'Company') (NASDAQ-FEIM), a leading provider of precision timing and frequency control products, today announced it will host the 2025 Quantum Sensing Summit on October 29–30, 2025, in New York City. The event will bring together leaders from government, industry, and research to accelerate the transition of quantum sensing technologies from the lab to mission-ready deployment. Building on the success of the inaugural 2024 summit, this year's two-day program will feature keynotes, panels, and technical sessions highlighting enabling technologies such as Rydberg and NV-diamond sensors, photonic integrated circuits (PICs), frequency combs, and ultra-low-noise oscillators. ' Quantum sensing is at the heart of the next technological revolution, ' said Dr. Tom McClelland, CEO of Frequency Electronics. 'This summit is designed to forge the partnerships and strategies that turn today's breakthroughs into tomorrow's deployable solutions.' The summit is expected to attract 100–150 participants, including key government decision-makers, program managers, and industry innovators, providing a unique forum for collaboration and policy influence in the emerging quantum technology landscape. About Frequency Electronics Frequency Electronics, Inc. (FEI) is a world leader in the design, development and manufacture of high precision timing, frequency generation and RF control products for space and terrestrial applications. FEI's products are used in satellite payloads and in other commercial, government and military systems including C4ISR and electronic warfare, missiles, UAVs, aircraft, GPS, secure communications, energy exploration and wireline and wireless networks. FEI-Zyfer provides GPS and secure timing capabilities for critical military and commercial applications; FEI-Elcom Tech provides Electronic Warfare ('EW') sub-systems and state-of-the-art RF and microwave products. FEI has received over 100 awards of excellence for achievements in providing high performance electronic assemblies for over 150 space and DOD programs. The Company invests significant resources in research and development to expand its capabilities and markets. FEI's Mission Statement: 'Our mission is to transform discoveries and demonstrations made in research laboratories into practical, real-world products. We are proud of a legacy which has delivered precision time and frequency generation products, for space and other world-changing applications that are unavailable from any other source. We aim to continue that legacy while adapting our products and expertise to the needs of the future. With a relentless emphasis on excellence in everything we do, we aim, in these ways, to create value for our customers, employees, and stockholders.' Forward-Looking Statements The statements in this press release regarding future earnings and operations and other statements relating to the future constitute 'forward-looking' statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, our inability to integrate operations and personnel, actions by significant customers or competitors, general domestic and international economic conditions, reliance on key customers, continued acceptance of the Company's products in the marketplace, competitive factors, new products and technological changes, product prices and raw material costs, dependence upon third-party vendors, other supply chain related issues, increasing costs for materials, operating related expenses, competitive developments, changes in manufacturing and transportation costs, the availability of capital, the outcome of any litigation and arbitration proceedings, and failure to maintain an effective system of internal controls over financial reporting. The factors listed above are not exhaustive and should be read in conjunction with the other cautionary statements that are included in this release and in our filings with the Securities and Exchange Commission. The Company's Annual Report on Form 10-K for the fiscal year ended April 30, 2024, filed on August 2, 2024 with the Securities and Exchange Commission includes additional factors that could materially and adversely impact the Company's business, financial condition and results of operations, as such factors are updated from time to time in our periodic filings with the Securities and Exchange Commission, which are accessible on the Securities and Exchange Commission's website at Moreover, the Company operates in a very competitive and rapidly changing environment. New factors emerge from time to time and it is not possible for management to predict the impact of all these factors on the Company's business, financial condition or results of operations or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, investors should not rely on forward-looking statements as a prediction of actual results. Any or all of the forward-looking statements contained in this press release and any other public statement made by the Company or its management may turn out to be incorrect. The Company expressly disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Globe and Mail
3 hours ago
- Globe and Mail
Pfizer's Elranatamab Study: Continued Access for Multiple Myeloma Patients
Pfizer Inc ((PFE)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Pfizer Inc. is conducting an Elranatamab Post Trial Access Study for participants with Multiple Myeloma, officially titled 'ELRANATAMAB POST TRIAL ACCESS: AN OPEN-LABEL, SINGLE-ARM STUDY FOR PARTICIPANTS WITH MULTIPLE MYELOMA CONTINUING FROM PFIZER-SPONSORED ELRANATAMAB CLINICAL STUDIES'. The study aims to provide continued access to elranatamab for patients who have shown clinical benefit in previous trials. This is significant as it supports ongoing treatment for patients with limited options. The intervention being tested is Elranatamab, a drug designed as a heterodimeric humanized full-length bispecific IgG2 kappa antibody. It targets BCMA on Multiple Myeloma cells and CD3 on T cells, aiming to enhance the immune response against cancer cells. The study is designed as an open-label, single-arm trial with no masking, focusing on treatment. All participants receive Elranatamab until disease progression, unacceptable toxicity, withdrawal of consent, study termination, or commercial availability of the drug in their country. The study began on October 3, 2023, and is currently recruiting. The last update was submitted on July 28, 2025. These dates are crucial for tracking the study's progress and understanding its timeline. This update may positively influence Pfizer's stock performance by demonstrating continued commitment to innovative cancer treatments. It may also impact investor sentiment favorably, especially in the context of competitive advancements in cancer therapies. The study is ongoing, with further details available on the ClinicalTrials portal.
